Ingmar Schuster

Our mission is to empower biotech innovators to streamline protein engineering campaigns, unlocking breakthrough possibilities for healthcare, sustainability, and industrial transformation. Exazyme harnesses cutting-edge artificial intelligence (AI) and machine learning (ML) technologies to revolutionize protein design, setting new standards in efficiency and precision. Our proprietary platform empowers biotech innovators across diverse industries—from pharmaceuticals to industrial and green biotechnology—to achieve their engineering goals with significantly fewer experimental cycles. By integrating state-of-the-art AI, bioinformatics, and proprietary methodologies, Exazyme enables the discovery of superior proteins with unparalleled performance. Traditional protein engineering methods are often constrained by limited data, high experimental costs, and suboptimal exploration of sequence spaces. Exazyme overcomes these limitations by combining robust AI models with prior biological knowledge and expert guidance. Our platform minimizes data requirements while ensuring model reliability and scalability, allowing for the exploration of vast sequence spaces and delivering remarkable performance gains. With Exazyme, protein engineers can reduce experimental efforts by up to 100x compared to standard approaches, drastically accelerating timelines while achieving superior outcomes. Exazyme’s achievements are backed by esteemed investors, including AIX Ventures and Atlantic Labs. Our work is co-financed by the IBB ProFIT program and the European Union’s EFRE program under the project “Protein Design and Molecular Design with Artificial Intelligence” (Application Numbers: 10196523/10196524).